CLINICAL TRIALS PROFILE FOR SEPTRA DS

All Clinical Trials for SEPTRA DS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000655 ↗	A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.
NCT00000655 ↗	A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.

Clinical Trial Conditions for SEPTRA DS

Condition Name

Condition Name for SEPTRA DS
Intervention	Trials
Urinary Tract Infection	5
Abscess	3
HIV Infections	2
Infection	2

Condition MeSH

Condition MeSH for SEPTRA DS
Intervention	Trials
Infections	8
Infection	8
Communicable Diseases	7
Urinary Tract Infections	5

Clinical Trial Locations for SEPTRA DS

Trials by Country

Trials by Country for SEPTRA DS
Location	Trials
United States	53
Canada	7
Belgium	3
Germany	2
United Kingdom	2

Trials by US State

Trials by US State for SEPTRA DS
Location	Trials
Texas	6
Washington	4
Ohio	4
New York	4
Missouri	4

Clinical Trial Progress for SEPTRA DS

Clinical Trial Phase

Clinical Trial Phase for SEPTRA DS
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for SEPTRA DS
Clinical Trial Phase	Trials
Completed	14
Recruiting	5
Unknown status	3

Clinical Trial Sponsors for SEPTRA DS

Sponsor Name

Sponsor Name for SEPTRA DS
Sponsor	Trials
National Cancer Institute (NCI)	4
University of Washington	3
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type for SEPTRA DS
Sponsor	Trials
Other	41
NIH	9
U.S. Fed	5